Breaking News

Harlan Labs Appoints BD Director

By Kristin Brooks | February 4, 2014

Guptato to head RMS Business Unit

Urvashi Gupta has been appointed director of business development for Harlan Laboratories Research Models and Services (RMS) business unit in Asia. Ms. Gupta will focus on expanding Harlan's market position and new business initiatives, including key strategic partnerships and leading corporate development efforts. She will also oversee a team of business development managers in Japan and Korea, and will have responsibility for agents in China, Singapore, Hong Kong, Malaysia and Australia.
 
Ms. Gupta has 13 years of experience in research, operations, client relations and sales throughout Asia, Europe and the U.S. Most recently, she served as business development manager for Covance, where she was responsible for all sales initiatives in India with a focus on expanding the company's presence throughout the region. She also worked as an operations manager and research scientist with Covance.

"As the preclinical research market continues to establish roots and grow outside of North America and Europe, now is the perfect time to expand our already talented business development group," said Stuart Frith, global vice president of business development at Harlan Laboratories. "We're excited to add Urvashi to our team, and her wealth of international experience in the CRO and pharmaceutical industries will be an asset to Harlan as we continue to expand in Asia."  

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important